Exelixis, Inc. is a oncology-focused biopharmaceutical company that discovers, develops, and commercializes cancer treatments. The company's key marketed product is cabozantinib, sold under the brand names Cabometyx and Cometriq, approved for renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. Exelixis also has a pipeline of additional oncology compounds in clinical development.
Q2 FY2026 — expected 2026-08-20
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-10 | 2026-01-02 | 0000939767-26-000021 | EDGAR | 46K words |
| 2025-02-11 | 2025-01-03 | 0000939767-25-000019 | EDGAR | — |
| 2024-02-06 | 2023-12-29 | 0000939767-24-000028 | EDGAR | — |
| 2023-02-07 | 2022-12-30 | 0000939767-23-000019 | EDGAR | — |
| 2022-02-18 | 2021-12-31 | 0000939767-22-000026 | EDGAR | — |
| 2021-02-11 | 2021-01-01 | 0001628280-21-001852 | EDGAR | — |
| 2020-02-25 | 2020-01-03 | 0000939767-20-000035 | EDGAR | — |
| 2019-02-22 | 2018-12-28 | 0000939767-19-000042 | EDGAR | — |
| 2018-02-26 | 2017-12-29 | 0000939767-18-000023 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-05 | 2026-07-03 | 0000939767-26-000098 | EDGAR | — |
| 2025-11-04 | 2025-10-03 | 0000939767-25-000128 | EDGAR | 26K words |
| 2025-07-28 | 2025-07-04 | 0000939767-25-000113 | EDGAR | — |
| 2025-05-13 | 2025-04-04 | 0000939767-25-000075 | EDGAR | — |
| 2024-10-29 | 2024-09-27 | 0000939767-24-000150 | EDGAR | — |
| 2024-08-06 | 2024-06-28 | 0000939767-24-000119 | EDGAR | — |
| 2024-04-30 | 2024-03-29 | 0000939767-24-000058 | EDGAR | — |
| 2023-11-01 | 2023-09-29 | 0000939767-23-000114 | EDGAR | — |
| 2023-08-01 | 2023-06-30 | 0000939767-23-000079 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000939767-23-000048 | EDGAR | — |
| 2022-11-01 | 2022-09-30 | 0000939767-22-000110 | EDGAR | — |
| 2022-08-09 | 2022-07-01 | 0000939767-22-000097 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-05 | 0000939767-26-000096 | EDGAR | — |
| 2026-02-10 | 0000939767-26-000019 | EDGAR | 5K words |
| 2026-01-12 | 0000939767-26-000003 | EDGAR | — |
| 2025-11-07 | 0000939767-25-000133 | EDGAR | — |
| 2025-11-04 | 0000939767-25-000127 | EDGAR | — |
| 2025-08-29 | 0000939767-25-000115 | EDGAR | — |
| 2025-07-28 | 0000939767-25-000111 | EDGAR | — |
| 2025-06-02 | 0000939767-25-000097 | EDGAR | — |
| 2025-05-13 | 0000939767-25-000074 | EDGAR | — |
| 2025-03-31 | 0000939767-25-000049 | EDGAR | — |
141 total filings indexed. 110 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000939767 |
| Ticker | EXEL |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.exelixis.com |
| Listed | 2000-04-11 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/EXEL (~200 tokens, structured JSON with cryptographic provenance)